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Abstract 
Objective: Grb2-associated binder 2 (Gab2), a member of the family of Gab scaffolding 
adaptors, transmits and amplifies the signals from receptor tyrosine kinases. A recent study 
demonstrated that Gab2 was over-expressed in breast cancers and metastatic melanomas, 
and Gab2 was an oncogenic protein. However, the roles of Gab2 in lung cancers are largely 
unknown.  
Method: In this study, to investigate whether Gab2 expression could be a characteristic of 
lung cancers, we analyzed the expression of Gab2 in 88 lung frozen tissue samples and 122 
paraffin-embedded tissue specimens, using quantitative real-time-PCR, immunohistochemis-
try and western blot. 
Results: We found that the positive expression rate of Gab2 in the tumor tissues, as detected 
by immunohistochemistry, 62.5% in squamous cell cancers, 51.35% in adenocarcinomas, and 
75% in other types of lung cancers, was significantly higher than that (12%) in normal lung 
tissues. The mRNA expression detected by quantitative real-time-PCR and protein expres-
sion detected by western blotting in different groups were consistent with the immuno-
histochemical results. 
Conclusion: Our data indicate that Gab2 is over-expressed in malignant lung tissues com-
pared with that in normal lung tissues, and suggest that Gab2 expression may play a role in 
lung cancer development. 
Key words: Gab2; lung cancer; quantitative real-time-PCR; immunohistochemistry; western blot 
Introduction 
Lung  cancer  is  the  leading  cause  of  cancer  re-
lated mortality in the world. It accounts for almost a 
million  deaths  annually  and  results  in  more  deaths 
than breast, gastric and colon cancers combined. The 
Grb2-associated  binder  (Gab)  proteins  including 
mammalian Gab1, Gab2 and Gab3, comprise a family 
of  scaffolding  or  docking  adaptor  proteins  [1].  Gab 
proteins are recruited to activated receptors by direct 
or indirect mechanisms,  mostly  indirectly via  Grb2. 
Gab2 undergoes tyrosine phosphorylation, creating a 
number of docking sites to mediate interactions with 
SH2 domain-containing proteins such as the tyrosine 
phosphatase SHP2 and the p85 subunit of PI3K. The 
interaction of Gab2 with SHP2 activates Ras-Erk sig-
naling, whereas its association with the p85 subunit of 
PI3K is crucial in mediating the PI3K-AKt signaling 
[2, 3]. 
Recent studies provide evidence that Gab2 plays 
a critical role in human cancer. Gab2 is overexpressed 
in breast cancers [4, 5]. Gab2(-/-) cancer cells exhib-
ited decreased migration and impaired Erk activation, 
suggesting  its  role  in  promoting  mammary  tumor Int. J. Biol. Sci. 2011, 7 
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metastasis  [6].  In  addition  to  breast  tumorigenesis, 
Gab2-mediated  signaling  has  been  implicated  in 
chronic  myelogenous  leukemia  and  lymphoid  leu-
kemia. The Grb2-Gab2 pathway is critical for leuke-
mic  transformation  by  Bcr-Abl  [7].  Although  these 
studies  suggest  the  importance  of  Gab2-mediated 
signaling  in  breast  cancer  and  leukemia,  its  role  in 
lung cancer is unclear. 
In  this  study,  we  identified  the  expression  of 
Gab2 in lung cancers by quantitative real-time-PCR, 
western blot and immunohistochemistry to explore its 
role in lung cancers. We found that Gab2 expression 
in lung tumor samples was significantly higher than 
that in normal lung samples, and Gab2 may be as a 
molecular marker for neoplastic progression.  
Materials and Methods 
Tissue samples 
All  the  specimens  were  obtained  from  Tianjin 
Medical University Tumor Hospital (from March to 
May 2010). The samples included 88 lung frozen tis-
sue samples and 122 Paraffin-embedded tissues (de-
tailed information is shown in Table 1). After obtain-
ing the fresh tissue specimens, we quickly put them 
into liquid nitrogen and stored them at -80°C. All in-
vestigations followed the tenets of the Declaration of 
Helsinki and were approved by the Review Board of 
the Tianjin Medical University Tumor Hospital. 
 
Table 1 Clinical characteristics of 119 patients (3 small cell carcinomas patients were not included). 
Characteristics  Normal  lung 
tissues 
Adenocarcinomas  Squamous  cell  carcino-
mas 
Other types 
Gender         
male  20  19  35  12 
female  5  18  5  5 
Age         
≥ 60  14  18  17  12 
< 60  11  19  23  5 
Tumor size         
≥ 4cm    14  25  9 
< 4cm    23  15  8 
Lymph node  
metastasis 
       
no    20  24  11 
yes    17  16  6 
Depth of invasion         
T1-T2    33  32  12 
T3-T4    4  8  5 
UICC* staging         
Ⅰ-Ⅱ    21  25  9 
Ⅲ-Ⅳ    16  15  8 
* UICC: International Union Against Cancer 
 
 
Quantitative Real-Time PCR 
Total RNAs were extracted from the frozen tis-
sue specimens by using the EZ-10 spin column total 
RNA  isolation  kit  (BioBasic,  Canada)  in  accordance 
with the manufacturer’s instructions. The frozen tis-
sue specimens included 15 lung tumor specimens and 
their corresponding normal lung cancer tissues (away 
from  the  tumor  >6cm  and  from  the  same  donor). 
cDNA was synthesized through using the superscript 
first  strand  synthesis  kit  as  per  instructions  of  the 
manufacturer(TakaRa, Japan). 1 μg total RNA and 50 
μmol/L  oligo(dT)18  were  incubated  at  70°C  for  10 
minutes, placed on ice for 2 minutes, and cDNA syn-
thesis mix was added. The reaction was incubated at 
42°C for 1 hour and terminated at 75°C for 15 minutes. 
Real-time quantitative PCR reaction contained 25μL 
2×SYBR Premix Ex Tap(TaKaRa, Japan), 2μL primer 
mix, 1μL50×ROX Reference Dye, 4μLcDNA, and 18μL 
deionized water to make a total volume of 50μL. All 
real-time PCR assays were performed in triplicate in a 
96-well  plate  using  the  7300  real  time  PCR  system 
(Applied  Biosystems,  USA).  Data  analysis  was  per-
formed using the SDS software (Applied Biosystems, 
USA)  and  the  results  were  expressed  at  a  relative Int. J. Biol. Sci. 2011, 7 
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mRNA  expression  level,  calculated  using  the  Pfaffl 
method with GAPDH as the reference gene [8].  
Western blot analysis 
58 frozen lung tissue specimens (20 normal lung 
tissues, 16 squamous cell carcinomas, 16 adenocarci-
nomas and 6 other types of lung cancers) were ho-
mogenized and lysed with RIPA buffer. Proteins were 
separated by SDS-polyacrylamide gel eleetrophoresis 
(PAGE),  transferred  to  0.45um  polyvinylidene  fluo-
ride by electroblotting. The membranes were blocked 
with 5% bovine serum albumin (BSA) in tris-buffered 
saline tween-20 (TBST) and then probed with GAB2 
antibody  (cell  signaling  technology,  Danvers,  MA, 
USA) at a 1:1000 dilution in TBST with 1%BSA over-
night. The membranes were then washed in TBST and 
probed with horseradish peroxidase-conjugated sec-
ondary antibodies at 1:5000 dilutions in TBST with 1% 
milk.  After  washing  in  TBST,  the  membranes  were 
developed  with  the  ECL  western  blotting  detection 
system  (Millipore,  USA).The  protein  band  density 
was  quantified  using  the  ImageJ  software  (Version 
1.38x), with β-actin (Abmart, China) as a loading con-
trol. The relative expression of Gab2 protein was ex-
pressed as the ratio of Gab2 expression to β-actin ex-
pression. 
Immunohistochemistry 
Formalin-fixed,  paraffin-embedded  tumor  tis-
sues  from  122  patients  (25  normal  lung  tissues,  40 
squamous cell carcinomas, 37 adenocarcinomas and 
20 other types of lung cancers) were sectioned (4 μm 
thick), mounted on poly-L-lysine-coated glass slides, 
and allowed to dry overnight at 37°C. Briefly, slides 
were  deparaffinized  in  xylene  and  transferred 
through  two  changes  of  100%  ethanol.  For  antigen 
retrieval, the slides were boiled in a pressure cooker at 
maximum heat for 2 minutes containing 0.01 mol/L 
sodium citrate (pH6.0) and cooling for 30 minutes at 
room  temperature.  Endogenous  peroxidase  activity 
was  blocked  in  0.3%  H2O2 for  10  minutes  at  37°C. 
Following incubation the slides were washed 3 times 
in PBS for 3 minutes each. Then slides were incubated 
with  the  primary  antibody  Gab2  antibodies  (Santa 
Cruz Biotechnology, sc-9313, USA) at 1:100 dilution 
overnight at 4°C. After washing with PBS, the bound 
primary  antibody  was  detected  by  using  a 
ready-to-use  secondary  antibody  kit  (Zhongshan 
Goldenbridge Biotech, Beijing, China) and the chro-
mogenic  substrate  3,3-diaminobenzidine  tetrahydro-
chloride(DAB).  The  specimens  were  counterstained 
with hematoxylin, mounted, and examined by light 
microscopy (Olympus BX50, Japan). 
Immunohistochemistry evaluation 
We utilized an immunohistochemical score (IHS) 
[9]  to  evaluate  of  the  immunohistochemical  results. 
An HIS score of 9-12 was considered strong immu-
noreactivity,  5-8  was  considered  moderate,  1-4  was 
considered weak, and 0 was scored as negative. 0-4 
were regarded as low expression, 5-12 were regarded 
as high expression. All of the slides were confirmed 
by the pathologist of tumor hospital and there were 
no  differences  in  interpretation  of  immunohisto-
chemical results between two pathologists. The per-
centage of positive cells was calculated by counting 
more  than  1000  cancer  cells  in  randomly  selected 
high-power  fields  (10  ×  40).  Routine  controls  using 
PBS instead of the primary antibody were included to 
verify specificity. 
Statistical analysis 
Statistical  analysis  was  carried  out  using  SPSS 
version 11.5. Paired samples t-test and one-way anal-
ysis of variance (ANOVA) were used to analyze the 
Gab2 expression in different group. Chi-square test or 
Fisher exact test was used to assess the relationship 
between Gab2 expression and clinic pathological fea-
tures. Differences were considered statistically signif-
icant when P- value was < 0.05. 
Results 
The mRNA expression of Gab2 in human lung 
cancers 
To identify whether Gab2 gene is critical for lung 
cancers, we examined Gab2 mRNA expression in 15 
lung cancer tissues and their corresponding normal 
lung tissues. All cases were available for evaluation of 
Gab2  mRNA  expression  by  quantitative  real-time 
PCR. The result showed that up-regulation of Gab2 
mRNA in 10 lung tumor samples compared to that in 
corresponding normal lung tissues, which were pe-
ripheral normal tissues from the same donor (Figure 
1).  Data  were  analyzed  by  paired-samples  t  test 
(t=2.632, P=0.020<0.05). 
The overexpression of Gab2 protein in human 
lung cancers  
We examined the expression of Gab2 protein in 
38 lung tumor samples (16 lung squamous cell carci-
nomas, 16 lung adenocarcinomas and 6 other types of 
lung cancers) and 20 normal lung samples by western 
blot analysis. Gab2 protein expressed at low levels in 
normal lung samples. However, lung tumor samples 
exhibited marked overexpression of Gab2 compared 
to the normal lung samples (Figure 2 A, B). Gab2 ex-
pression  in  38  lung  tumor  samples  and  20  normal 
lung samples was analyzed using the ImageJ software Int. J. Biol. Sci. 2011, 7 
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(Version  1.38x).  Results  showed  that  Gab2  protein 
expressions were significantly higher in lung tumor 
samples than that in  normal lung tissues (Figure 3, 
P=0.0023, A one-way analysis of variance), but there is 
no statistical significance of Gab2 expression among 3 
groups of lung tumor samples. 
 
 
Figure 1. Gab2 mRNA was overexpressed in lung tumor specimens. The mRNA expression of Gab2 was examined in 15 
normal lung tissues and 15 lung tumor tissues by real time PCR.  
 
 
Figure 2. Gab2 protein was overexpressed in lung cancers. Gab2 protein expression of 58 lung tissue specimens was 
measured by western blot analysis. β-actin was used as a loading control. Gab2 expression was very low in normal lung 
tissues, whereas it was overexpression in lung cancer tissues. (A) The representing pictures of Gab2 and β-actin protein 
expression. (B) The ratio of Gab2 expression to β-actin expression was shown. 
 
 Int. J. Biol. Sci. 2011, 7 
 
 
http://www.biolsci.org 
500 
To characterize Gab2 expression in normal and 
malignant lung tumor tissues, immunohistochemical 
analysis was performed. Most of lung tumor tissues 
showed strong cytoplasmic staining with Gab2, and a 
few  showed  nucleolus  staining.  Rare  cells  showing 
Gab2 positive staining were identified in the normal 
lung tissues (Figure 4 A, B, C, D).  
22 of 25 normal lung tissues were negative for 
Gab2, and only 3 were positive. In contrast, 51.35% 
(19/ 37) lung adenocarcinomas, 62.5% (25 / 40) lung 
squamous  cell  carcinomas  and  75%  (15  /20)  other 
types of lung cancer tissue specimens showed positive 
immunoreactivity  for  Gab2  antibody,  exhibiting  an 
increased intensity of staining compared with that of 
normal lung tissues specimens. 20 other types of lung 
cancers included 1 lymphoepithelioma-like carcinoma 
of  the  lung,  1  basaloid  squamous  carcinoma  of  the 
lung, 2 malignant tumors, 3 small cell carcinomas, 4 
pulmonary sarcomatoid carcinomas, 4 large cell car-
cinomas and 5 adenosquamous carcinomas. Results of 
Gab2 protein expression score were shown in Figure 5 
(P<0.01, chi square test), but there is no statistical sig-
nificance of Gab2 expression among 3 groups of lung 
tumor specimens.  
We make a further study to assess the relation-
ship between Gab2 expression and clinic pathological 
features. There are only 17 other types of lung cancer 
specimens,  except  3  small  cell  carcinomas,  so  we 
mainly  analyzed  the  relation  between  Gab2  expres-
sion and clinic pathological features of patients with 
lung adenocarcinomas and squamous cell carcinomas. 
We found that Gab2 expression was related to tumor 
size (P=0.0170) and UICC staging (P=0.0079) in lung 
adenocarcinomas and squamous cell carcinomas, re-
spectively, but not to age, gender, histological grade, 
lymph node metastasis and depth of invasion (Table 
2). 
 
 
Figure 3. Data shown in this figure was from the 58 lung frozen tissue specimens (20 normal lung tissues, 16 adenocar-
cinomas, 16 squamous cell carcinomas and 6 other types of lung cancers) (
*compared to the normal lung tissues, P<0.05), 6 
other types of lung cancers include 1 small cell carcinoma, 1 large cell carcinoma, 1 basaloid squamous carcinoma of the lung, 
1 malignant tumor and 2 adenosquamous carcinoma. 
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Figure 4. Gab2 immunoreactivity in normal lung tissues and lung tumor tissues. The panels showed representative pho-
tomicrographs of Gab2 expression detected by immunohistochemistry. (A) Paraffin-embedded normal lung tissues, staining 
negatively for Gab2. (B) Gab2 immunoreactivity in lung adenocarcinoma specimens. (C) Gab2 expression in lung squamous 
cell carcinoma tissues (D) Gab2 expression in large cell carcinomas, staining positively the same as the B and C. (A,B,C,D left 
100×magnification; right 400×magnification). 
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Figure 5. The Gab2 protein expression score in the 122 paraffin-embedded lung tissues, including 25 normal lung tissues, 37 
adenocarcinomas, 40 squamous cell carcinomas and 20 other types of lung cancers ( 
*compared to the normal lung tissues, 
P<0.01). All data were obtained under 400 × high-power magnification. 
 
Table 2 Gab2 expression and clinic pathological features of patients with lung adenocarcinomas and squamous cell car-
cinomas. 
characteristics  Gab2 expression of lung adenocarcinomas  Gab2 expression of lung squamous cell carcinomas 
low  high  P values  low  high  P values 
Gender             
male  8  11    13  22   
female  10  8  0.5171  2  3  1.0000 
Age             
≥ 60  10  8    6  11   
< 60  8  11  0.5171  9  14  0.8040 
Tumor size             
≥ 4cm  3  11    9  16   
< 4cm  15  8  0.0170*  6  9  0.8003 
Lymph node 
 metastasis 
           
no  10  10    10  14   
yes  8  9  1.0000  5  11  0.5050 
Depth of  
invasion 
           
T1-T2  18  15    13  19   
T3-T4  0  4  0.1050  2  6  0.6857 
UICC  
staging 
           
Ⅰ-Ⅱ  12  9    12  8   
Ⅲ-Ⅳ  6  10  0.3245  3  17  0.0079* 
Histologic grade             
well-moderate         9  16   
poor        6  9  0.8000 
* P<0.05 
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Discussion 
As  bona  fide  signal  transducers,  Gab  proteins 
also contain features that are  involved in the trans-
duction and amplification of receptor-derived signals. 
The  Gab2  is  increasingly  implicated  in  JAK/STAT 
signaling [10] and Gab2-deficient mice also display an 
osteopetrotic phenotype that is explained by the role 
of Gab2 as a key regulator of RANK signaling [11]. A 
recent study showed that activation of PI3K by c-Kit is 
dependent  both  on  the  direct  PI3K-binding  site  in 
c-Kit and the phosphorylation of Gab2 [12]. Through 
the  recruitment  of  PI3K  to  activated  receptors,  Gab 
proteins  contribute  to  the  initiation  of  signaling 
pathways  promoting  cellular  growth,  survival,  mi-
gration and proliferation [3]. 
Gab2 is developing a strong track record as an 
oncoprotein in various solid tumors. Firstly, Gab2 is 
frequently  over-expression  in  human  breast  cancer 
cell lines and primary tumors, especially in the ductal 
carcinoma in situ (DCIS) [13]. The original study on 
Gab2 in breast cancer demonstrated that the high ex-
pression  of  both  Gab2  mRNA  and  protein  was  de-
tected  in  the  majority  of  the  estrogen  receptor 
(ER)-positive lines [4]. Over-expression of the human 
Gab2 gene has also been reported recently for ovarian 
[14],  gastric  cancer  [15]  and  acute  myeloid  leuke-
mia(AML) [16]. Some researchers also find that GAB2 
modifies late-onset Alzheimer's disease (LOAD) risk 
in APOE epsilon4 carriers and influences Alzheimer's 
neuropathology [17, 18]. Gab2 is also over-expression 
in metastatic melanoma and low expression levels in 
melanocytic  nevi  and  primary  melanomas  [2],  sug-
gesting that Gab2 overexpression might  represent a 
marker of neoplastic progression. 
 However, the role of Gab2 in lung cancers has 
not been reported. In this study, we use 88 lung frozen 
tissue samples and paraffin-embedded tumor tissues 
from  122  patients  to  investigate  the  expression  of 
Gab2  in  lung  cancers.  We  find  that  Gab2  is 
over-expression  in  lung  cancer  tissue  specimens  of 
both mRNA and protein, compared to a low expres-
sion levels in normal lung tissue specimens. Our re-
sults support the findings from the breast cancer and 
the metastatic melanomas of human.  
Gab2 can stimulate both Erk and AKT signaling 
through its interactions with SHP2 and p85 subunit of 
PI3K respectively. 11q13-14 amplification is observed 
in several types of malignancy including melanoma 
[19], breast [20, 21], and ovarian cancer [22]. We do 
not demonstrate which signaling transduction path-
way is involved in lung cancer, and a further study 
should  be  made  in  the  future.  But,  a  recent  study 
showed that association of c-Met with PI3K and Gab2 
was diminished by inhibiting c-Met in small cell lung 
cancer [23] and ablation of Gab2 severely suppressed 
lung metastasis [6], suggesting Gab2 may be an im-
portant  therapeutic  target.  Our  findings  highlight  a 
novel role of Gab2 in lung cancers and underscore the 
potential utility of Gab2 as a target for new molecular 
directed therapies. 
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